These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 10223249)

  • 1. Serum CA125 elevation and risk of clinical detection of cancer in asymptomatic postmenopausal women.
    Jeyarajah AR; Ind TE; Skates S; Oram DH; Jacobs IJ
    Cancer; 1999 May; 85(9):2068-72. PubMed ID: 10223249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased mortality in postmenopausal women with serum CA125 elevation.
    Jeyarajah AR; Ind TE; MacDonald N; Skates S; Oram DH; Jacobs IJ
    Gynecol Oncol; 1999 May; 73(2):242-6. PubMed ID: 10329041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation.
    Menon U; Talaat A; Jeyarajah AR; Rosenthal AN; MacDonald ND; Skates SJ; Sibley K; Oram DH; Jacobs IJ
    Br J Cancer; 1999 Jul; 80(10):1644-7. PubMed ID: 10408412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized study of screening for ovarian cancer: a multicenter study in Japan.
    Kobayashi H; Yamada Y; Sado T; Sakata M; Yoshida S; Kawaguchi R; Kanayama S; Shigetomi H; Haruta S; Tsuji Y; Ueda S; Kitanaka T
    Int J Gynecol Cancer; 2008; 18(3):414-20. PubMed ID: 17645503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer.
    Menon U; Skates SJ; Lewis S; Rosenthal AN; Rufford B; Sibley K; Macdonald N; Dawnay A; Jeyarajah A; Bast RC; Oram D; Jacobs IJ
    J Clin Oncol; 2005 Nov; 23(31):7919-26. PubMed ID: 16258091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does serum CA125 have clinical value for follow-up monitoring of postoperative patients with epithelial ovarian cancer? Results of a 12-year study.
    Guo N; Peng Z
    J Ovarian Res; 2017 Mar; 10(1):14. PubMed ID: 28284216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre- and postmenopausal high-risk women undergoing screening for ovarian cancer: anxiety, risk perceptions, and quality of life.
    Hensley ML; Robson ME; Kauff ND; Korytowsky B; Castiel M; Ostroff J; Hurley K; Hann LE; Colon J; Spriggs D
    Gynecol Oncol; 2003 Jun; 89(3):440-6. PubMed ID: 12798709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors influencing serum concentration of CA125 and CA15-3 in Iranian healthy postmenopausal women.
    Dehaghani AS; Ghiam AF; Hosseini M; Mansouri S; Ghaderi A
    Pathol Oncol Res; 2007; 13(4):360-4. PubMed ID: 18158573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening.
    Menon U; Talaat A; Rosenthal AN; Macdonald ND; Jeyerajah AR; Skates SJ; Sibley K; Oram DH; Jacobs IJ
    BJOG; 2014 Dec; 121 Suppl 7():35-9. PubMed ID: 25488086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CA125 reference values change in male and postmenopausal female subjects.
    Cartei G; Cartei F; Bertin M; Padoan A; Zustovich F; Nicoletto MO; Plebani M
    Clin Chem Lab Med; 2013 Feb; 51(2):413-9. PubMed ID: 23006901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status.
    Skates SJ; Mai P; Horick NK; Piedmonte M; Drescher CW; Isaacs C; Armstrong DK; Buys SS; Rodriguez GC; Horowitz IR; Berchuck A; Daly MB; Domchek S; Cohn DE; Van Le L; Schorge JO; Newland W; Davidson SA; Barnes M; Brewster W; Azodi M; Nerenstone S; Kauff ND; Fabian CJ; Sluss PM; Nayfield SG; Kasten CH; Finkelstein DM; Greene MH; Lu K
    Cancer Prev Res (Phila); 2011 Sep; 4(9):1401-8. PubMed ID: 21893500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors influencing serum CA125II levels in healthy postmenopausal women.
    Pauler DK; Menon U; McIntosh M; Symecko HL; Skates SJ; Jacobs IJ
    Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):489-93. PubMed ID: 11352859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
    Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum CA 125 combined with transvaginal ultrasonography for ovarian cancer screening.
    Roupa Z; Faros E; Raftopoulos V; Tzavelas G; Kotrotsiou E; Sotiropoulou P; Karanikola E; Skifta E; Ardavanis A
    In Vivo; 2004; 18(6):831-6. PubMed ID: 15646829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening.
    Menon U; Talaat A; Rosenthal AN; Macdonald ND; Jeyerajah AR; Skates SJ; Sibley K; Oram DH; Jacobs IJ
    BJOG; 2000 Feb; 107(2):165-9. PubMed ID: 10688498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of a normal level of serum CA125 in postmenopausal women as a tool for preoperative evaluation and postoperative surveillance of endometrial carcinoma.
    Kurihara T; Mizunuma H; Obara M; Andoh K; Ibuki Y; Nishimura T
    Gynecol Oncol; 1998 Jun; 69(3):192-6. PubMed ID: 9648586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and validation of circulating CA125 prediction models in postmenopausal women.
    Sasamoto N; Babic A; Rosner BA; Fortner RT; Vitonis AF; Yamamoto H; Fichorova RN; Titus LJ; Tjønneland A; Hansen L; Kvaskoff M; Fournier A; Mancini FR; Boeing H; Trichopoulou A; Peppa E; Karakatsani A; Palli D; Grioni S; Mattiello A; Tumino R; Fiano V; Onland-Moret NC; Weiderpass E; Gram IT; Quirós JR; Lujan-Barroso L; Sánchez MJ; Colorado-Yohar S; Barricarte A; Amiano P; Idahl A; Lundin E; Sartor H; Khaw KT; Key TJ; Muller D; Riboli E; Gunter M; Dossus L; Trabert B; Wentzensen N; Kaaks R; Cramer DW; Tworoger SS; Terry KL
    J Ovarian Res; 2019 Nov; 12(1):116. PubMed ID: 31771659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women.
    Skates SJ; Menon U; MacDonald N; Rosenthal AN; Oram DH; Knapp RC; Jacobs IJ
    J Clin Oncol; 2003 May; 21(10 Suppl):206s-210s. PubMed ID: 12743136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of ovarian cancer among women with a CA125 level of 35 U/ml or less.
    Kobayashi H; Yamada Y; Sado T; Sakata M; Yoshida S; Kawaguchi R; Kanayama S; Shigetomi H; Haruta S; Tsuji Y; Ueda S; Kitanaka T; Oi H
    Gynecol Obstet Invest; 2008; 65(2):133-8. PubMed ID: 17957102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women.
    Cho HY; Park SH; Park YH; Kim HB; Kang JB; Hong SH; Kyung MS
    J Korean Med Sci; 2015 Dec; 30(12):1777-83. PubMed ID: 26713052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.